When was METiS Therapeutics founded?

METiS Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is METiS Therapeutics located?

METiS Therapeutics is headquartered in Cambridge, United States.

Is METiS Therapeutics a funded company?

METiS Therapeutics is a funded company, having raised a total of $252M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 23, 2020.

When was the latest funding round of METiS Therapeutics?

METiS Therapeutics' latest funding was a $***** Series B round on Apr 05, 2022, with participation from 6 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.88B in funding in 2026 to date.

Where does METiS Therapeutics rank among its competitors?

METiS Therapeutics ranks 29th amongst 270 active competitors, of which 83 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Tandem AI, which secured $22M in Nov, 2025.

Who are the top competitors of METiS Therapeutics?

METiS Therapeutics' top competitors include Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics. Among them, Tandem AI secured the most recent funding round in November, 2025.

METiS Therapeutics - 2026 Company Profile, Team, Funding & Competitors

METiS Therapeutics is a series B company based in Cambridge (United States), founded in 2017 by Wenshou Wang. It operates as a Provider of an AI-assisted platform for drug discovery and development. METiS Therapeutics has raised $252M in funding from investors like Sequoia Capital China, Luminous Ventures and China Life Insurance. The company has 270 active competitors, including 83 funded and 15 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics.

Company Details

Provider of an AI-assisted platform for drug discovery and development. The company utilizes machine learning algorithms to identify clinical candidate molecules with the advanced prediction of pharmaceutical properties. It aids researchers with the optimization and selection of small molecules for different therapeutic purposes.

Website: www.metistx.com/
Social
Email ID: *****@metistx.com

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Series B

Total Funding

$252M in 5 rounds

Latest Funding Round

Series B, Apr 05, 2022, $*****

Investors

Sequoia Capital China & 14 more

Ranked

29^th among 270 active competitors

Similar Companies

Schrodinger & 277 more

View METiS Therapeutics' full profile

METiS Therapeutics has raised a total funding of $252M over 5 rounds. Its first funding round was on Mar 23, 2020. Its latest funding round was a Series B round on Apr 05, 2022 for $*****. 6 investors participated in its latest round. METiS Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of METiS Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 05, 2022	8650361	Series B	3335800	3368864	1085688	3003516
Dec 07, 2021	9384218	Series A	3826780	6092168	8875073	Sequoia Capital & 4 more
Dec 03, 2020	6677053	Angel	9679912	8837454	Sequoia Capital China & 1 more	3939824

Access funding benchmarks and valuations. Sign up today!

View details of METiS Therapeutics's funding rounds and investors

The founders of METiS Therapeutics is Wenshou Wang.

Here are the details of METiS Therapeutics' key team members:

Wenshou Wang: Co-Founder of METiS Therapeutics and founder of 1 other company.
Contact Info: 2 email addresses

View details of METiS Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of METiS Therapeutics include Schrodinger, Recursion Pharmaceuticals and Relay Therapeutics. Here is the list of Top 10 competitors of METiS Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 48 others	72/100
3rd	Relay Therapeutics 2016, Cambridge (United States), Public	Developer of drug discovery platform and study protein motion	$520M	BVF Partners, SoftBank Vision Fund & 17 others	70/100
4th	Atomwise 2012, San Francisco (United States), Series B	Developer of artificial intelligence platform for small molecule drug discovery	$219M	DCVC, B Capital & 27 others	67/100
5th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	67/100
6th	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, Orbimed & 25 others	67/100
7th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
8th	In Silico 2014, Boston (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Value Partners & 36 others	63/100
9th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
10th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, R42 Group & 19 others	62/100
29th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	5Y Capital, CMB International Capital & 13 others	55/100